Background: Epilepsy is a common neurological disorder characterized by recurrent seizures, along with comorbid cognitive and psychosocial impairment. Current gold standards of assessment can quantify cognitive and motor performance, but may not capture all subtleties of behavior. Here, we study the feasibility of assessing various upper limb sensorimotor and cognition functions in people with epilepsy using the Kinarm robotic assessment system. We quantify performance across multiple behavioral domains and additionally consider the possible effects of epilepsy subtype and medication. Methods: We recruited individuals with a variety of epilepsy subtypes. Participants performed 8 behavioral tasks that tested motor, cognitive, and sensory domains. We collected data on the same tasks from a group of control participants that had no known neurological impairments. We quantified performance using Task Scores, which provide a composite measure of overall performance on a given task and are adjusted for age, sex, and handedness. Results: We collected data from 46 individuals with epilepsy and 92 control participants. The assessment was well-tolerated, with no adverse events recorded. Cognitive tasks testing spatial working memory, executive function, and motor response inhibition were the most frequently impaired in the epilepsy cohort, with 33/46 (72%) being outside the normal range on at least one of these tasks. Additionally, 29/46 (63%) were impaired on at least one task testing primarily motor skill, and 14/46 (30%) were impaired on a proprioceptive sensory task. People with either focal epilepsy or generalized epilepsy performed significantly worse on both motor and cognitive tasks than control participants after correcting for multiple comparisons. There were no statistical differences between generalized and focal epilepsy groups on Task Scores. Finally, individuals taking topiramate trended toward having worse performance on a spatial working memory task than other individuals with epilepsy who were not taking topiramate. Conclusions: Kinarm robotic assessment is feasible in individuals with epilepsy and is well-tolerated. Our robotic paradigm can detect impairments in various sensorimotor and cognitive functions across the population with epilepsy. Future studies will explore the role of epilepsy subtype and medications.
Introduction
Epilepsy is a diverse condition encompassing a range of clinical subtypes and severities. The most widely studied deficits in epilepsy are the classic cognitive deficits in memory, language, and executive functions; however, deficits in other domains such as psychomotor speed also exist, either as a result of epilepsy itself or as a result of pharmacotherapy [1] [2] [3] [4] [5] . More precise detection of these deficits could improve our understanding of cognitive deficits in epilepsy and the adverse effects of medication.
In epilepsy, the most commonly used neuropsychological assessment tools emphasize the cognitive domains that are known to be impacted in specific epilepsy syndromes [2, 4] . Neuropsychological evaluations sometimes quantify sensorimotor skills (e.g., finger tapping speed), but the measures are fairly limited with coarse quantification [1, 2] . Thus, there has been limited research to characterize the nature and extent of sensorimotor impairment in patients with epilepsy, even though they are apparent to clinicians and their existence has occasionally been documented in the research literature [6, 7] . It can be time-consuming to broadly measure cognitive and psychomotor performance in patients with epilepsy. The pervasiveness of cognitive deficits in this disorder means that understanding their extent in patients in detail is valuable, and could potentially highlight behavioral changes pertaining to medications. For example, lamotrigine and topiramate have different effects on cognition [8] . It would be beneficial to explore the potential of novel technologies to gather behavioral data in this population, as they could identify impairments in multiple domains with greater detail than is currently possible. Furthermore, they may be able to detect subtle changes in behavior that could be attributed to specific medications that could escape detection using standard clinical tools.
Robotic assessment is a promising technique for gathering objective and granular behavioral data efficiently and reproducibly [9] [10] [11] [12] [13] . The Kinarm robotic assessment system (Kinarm, Kingston, ON, Canada) is a tool that quantifies performance on a collection of behavioral tasks that test motor, cognitive, and sensory functions, referred to as Kinarm Standard Tests™ (KSTs). It has been used to characterize deficits in a variety of clinical populations such as stroke ( [14] [15] [16] ), ALS [17] , Parkinson's disease [18] , TIA [19] , and concussion [20] . Furthermore, previous work has highlighted the test-retest reliability of Kinarm assessment results [21] . Here, we will investigate the feasibility of using Kinarm to quantify deficits on behavioral tasks in patients with a variety of epilepsy subtypes. Our objective is to determine the feasibility of using Kinarm robotic assessment with this patient population. Additionally, we investigate whether we can detect differences between epilepsy subtypes, and whether we can detect differences between individuals using different medications.
Methods

Participants
Participants were recruited from the epilepsy clinic at Kingston Health Sciences Centre (Hotel Dieu Hospital site) in Kingston, ON, Canada with the assistance of an experienced epileptologist (LBL). Inclusion criteria were as follows: 1) diagnosis of epilepsy and being followed in clinic; 2) able to understand the instructions of the robotic assessment (i.e., at most cognitive deficits that were apparently mild); and 3) not known to experience reflex seizures in response to video stimuli. This study was approved by the Queen's University Research Ethics Board.
Clinical assessment
The clinical assessment component of the study included the collection of demographic and clinical information and administration of the Montreal Cognitive Assessment (MoCA) [22] . The MoCA is a brief, widely used, cognitive screening instrument testing language, visuospatial ability, attention, memory, and executive functions. As per recent recommendations, an extra point was added to the total raw score (maximum 30) if education was b 12 years. Medications and dosages were recorded, and were later verified by an experienced epileptologist (GPW).
Robotic assessment
See Fig. 1 for a depiction of the robotic apparatus and illustrations of the behavioral tasks used in this assessment. Participants performed behavioral tasks using the Kinarm Exoskeleton or Endpoint Lab (Kinarm, Kingston, ON, Canada). To perform the behavioral tasks, participants were seated and rested their arms in troughs attached to the robot to support the weight of the arm (Exoskeleton only) or gripped handles without support of the upper limbs (Endpoint). Participants looked down at a semitransparent screen, onto which tasks were projected from above. Participants moved their hands underneath the screen and feedback of the position of the hand was provided on the screen in most tasks, although participants could not directly see their hands as they were obscured with a vision blocker.
The robotic assessment battery consisted of 8 tasks that tested motor and sensory performance in the upper limbs, as well as cognition. Motor tasks consisted of Visually Guided Reaching (VGR) [14] , Object Hit (OH) [23] , Object Hit-and-Avoid (OHA) [24] , and Ball on Bar (BOB) [25] . Proprioception (an aspect of sensory behavior) was assessed using the Arm Position Matching (APM) task [26] . Cognition (including response inhibition, spatial working memory, and set-switching) was assessed using the Reverse Visually Guided Reaching (RVGR) [27] , Spatial Span (SPS) [19, 28] , and Trailmaking (TMT) [29] tasks. Detailed descriptions of these tasks are provided in Table 1 . Note that BOB, OH, and OHA require the use of both hands simultaneously, while each limb is tested separately for VGR, RVGR, and APM; SPS and TMT are performed using the dominant arm only.
Statistical analysis
The KINARM behavioral tasks quantify many spatial and temporal aspects of behavior using various units (sec., m/s, number of targets, etc.), which we refer to as task "parameters." These parameters were converted into Z-scores based on performance of large cohorts of healthy control subjects, considering the influence of age, sex, handedness, and robotic platform on performance (Dexterit-E, version 3.7, Kinarm, Kingston, Canada). Task Scores were also computed based on the root mean square of all parameters in a task and transformed into a one-sided (positive) value ranging from 0 to + infinity, with lower values representing good overall performance and higher values representing poor overall performance. The percentiles of the Task Score cumulative distribution function (CDF) roughly approximate those of the standard Normal CDF, and therefore, we consider values above 1.96 to be outside the performance envelope of 95% of controls and, therefore, to represent impairment ( Fig. 1 ). The normalization process and Task Scores have been described previously [19] (see also https://kinarm.com/kinarm-products/kinarm-standard-tests).
To compare Task Scores between different subgroups, we performed t-tests assuming unequal variance. We compared pairs of epilepsy subgroups: generalized and focal epilepsy, as well as right and left temporal lobe epilepsy (TLE), and as such we corrected for multiple comparisons using the Bonferroni method for adjusting the family-wise error rate (FWER). Spearman correlations were additionally performed to consider the relationship between the MoCA total score and robotic variables. Chi-square tests were used to compare the proportions of epilepsy and control participants impaired in each behavioral domain under study. Statistical analyses were performed using SciPy and NumPy libraries in Python 3.7.
Results
Demographics and clinical assessments
We collected data from 46 individuals with epilepsy. Nineteen individuals were assessed using the Kinarm exoskeleton during early data collection, and the remaining 27 were assessed using the Kinarm Endpoint robot, because it has a faster setup time than the Exoskeleton and the normalization process for all scores ensured that the data would be comparable across-platforms. See Table 2 for demographic information of individuals with epilepsy. Of the participants in the epilepsy cohort, 32 (70%) were female and 44 (96%) were right-handed. The median [interquartile range (IQR)] age was 46.2 [32.3] (range: 18-79) years. The most common medication was lamotrigine (taken by 25 people), followed by topiramate and lacosamide (each taken by 8 people). On average, people in the epilepsy cohort were taking 2.1 ± 1.0 antiepileptic drugs (AEDs). In individuals with generalized epilepsy, this number was 2.3 ± 0.9, and in individuals with focal epilepsy it was 2.0 ± 1.1. This difference is not statistically significant (t(42) = 0.89, p N .05). The most common diagnoses were generalized epilepsy (15 total including 4 individuals with juvenile myoclonic epilepsy, JME) and TLE (13 individuals).
We quantified the MoCA score in the population of people with epilepsy. The median [IQR] MoCA score was 26.5 [3.8] , with 19/46 (41%) individuals falling under the threshold of 26 previously defined by the creators of the test when screening for mild cognitive impairment [22] . However, only 6/46 (13%) individuals were below a score of 23, which may be more representative of the general population's performance on this test as determined in a later validation study [31] . , and overview of the properties of the Task Score. A) Participants were seated and grasped handles to move the robotic arms. Participants performed the tasks by moving their arms in the horizontal plane underneath a screen onto which the tasks were projected. Direct vision of the participants' hands was obscured. Early data collection used the Kinarm Exoskeleton (not pictured [19] ). B) There are 8 KSTs, 4 testing motor behavior (VGR, BOB, OH, OHA), 3 testing cognition (RVGR, SPS, TMT), and 1 testing sensory capability (APM). C) Task Score cumulative density function (CDF) approximates that of the standard Normal distribution, and so the quantiles are similar.
Finally, we compared the group with epilepsy to a cohort of 92 healthy control participants that had been previously assessed on all 8 tasks and form part of the cohort used to develop the normative scores for KST [32] . In controls, 28/46 (60%) were female and 38/46 (83%) were right-handed. The median [IQR] age was 46.2 [32.3] (range: 18-83) years. The difference in the age distribution for individuals with epilepsy and the control cohort does not impact robot-based measures as scores are adjusted for the influence of age.
Feasibility
This is the first time that Kinarm has been used to assess individuals with epilepsy; we, therefore, first sought to determine whether or not it is feasible to assess individuals in this population in this way. Overall, the paradigm that we used was well-tolerated by all individuals in the cohort. Of 46 individuals with epilepsy examined in this study, none experienced adverse events as a result of the robotic assessment. One individual experienced a seizure prior to robotic assessment when trying to recall their medication doses but was able to continue with the exam after recovering. One assessment was incomplete due to time constraints, but no participant reported discomfort or excessive difficulty with the tasks. The median [IQR] time to complete the robotic assessments was 36.0 [5.8] min.
Robotic tasks
Participants performed a battery of 8 robotic behavioral tasks that tested upper-limb motor and sensory performance, as well as cognition. We report Task Scores as our method of identifying impairments on robotic assessment tasks. Fig. 2 provides an overview of Task Scores for the cohort with epilepsy and control cohort. Out of the participants in the epilepsy group that completed all of the motor tasks, 29/46 (63%) were outside the 95% range of healthy controls on at least 1 motor task. Similarly, 33/46 (72%) were impaired on at least 1 cognitive task. Finally, 13/46 (28%) were impaired on APM in either limb. In control participants, these numbers were: 25/92 (27%; motor), 22/92 (24%; cognitive), and 9/92 (10%; sensory), respectively. The domain-wise proportions of impairments in the epilepsy cohort were significantly different from the control participants (all p b .01).
Performance across domains
Performance on individual tasks
We computed Task Scores on 4 tasks that tested primarily motor behavior: VGR, BOB, OH, and OHA. Task Scores identified that 15/46 (33%) individuals were impaired on VGR (dominant arm) and 14/46 (30%) on VGR (nondominant arm). We identified that 8/46 (17%) were impaired on BOB. Similarly, 15/46 (33%) were impaired on OH and 15/46 (33%) were impaired on OHA. In controls, these numbers were 7/92 (8%), 4/ 92 (4%), 7/92 (8%), 5/92 (5%), and 6/92 (7%), respectively.
Task Scores were collected for 3 tasks that incorporated elements to test cognition: RVGR, TMT, and SPS. Of these, 20/46 (44%) of individual with epilepsy were impaired on RVGR (dominant arm), 16/46 (35%) in RVGR (nondominant arm), 10/46 (22%) were impaired on SPS, and 22/ 46 (48%) were impaired on TMT. In the control group, 12/92 (13%) were impaired on RVGR (dominant arm) and 14/92 (15%) in the nondominant arm, 2/92 (2%) were impaired on SPS, and 3/92 (3%) were impaired on TMT.
Finally, 11/46 (24%) and 6/46 (13%) of individuals in the cohort with epilepsy were impaired in APM in the dominant and nondominant arms, respectively. In the control cohort, these numbers were 6/92 (7%) and 5/92 (5%), respectively. Fig. 3 displays the cumulative sum plots of Task Scores across individuals with epilepsy and control participants. Note the cumulative distribution for healthy controls quickly rises such that~50% of subjects have a score b 0.3 to 0.8 depending on the task. In contrast, the distribution for individuals with epilepsy is shifted to the right with substantial proportions with scores N 1.96.
We compared people in the cohort with epilepsy to those in the control cohort, and also split the cohort with epilepsy into individuals with generalized epilepsy and those with focal epilepsy (2 had indeterminate diagnoses and were excluded from this analysis); see Fig. S1 . After correction for FWER, individuals in the cohort with epilepsy had significantly higher Task Scores on all tasks except for APM-ND and BOB (p b .001). After correction for FWER, participants with focal epilepsy had significantly higher Task Scores than controls on SPS (t(121) = 3.64, p b .001) and TMT (t(121) = 5.45, p b .0001), reflecting greater cognitive impairment in the group with focal epilepsy. After correction for multiple comparisons, individuals with generalized epilepsy had significantly higher Task Scores than controls on TMT (t(107) = 4.33, p b .001) and VGR (both arms; VGR-D: t(107) = 4.69, p b .001; VGR-ND: t(107) = Table 1 Task descriptions.
Task Description
Arm position matching (APM)
In this task, the robot moved one of the participant's arms (the 'active' arm) and the participant was required to mirror-match the position of their active arm with their other arm. The goal of the task was to match position as accurately as possible and was not timed [26] . Visually guided reaching (VGR)
VGR required participants to reach quickly and accurately from a central target to a sequence of 4 peripheral targets [14, 15] . This task tests the ability to make smooth and accurate reaches.
Ball on bar (BOB)
Participants were required to move a ball balanced on a bar to a sequence of 4 targets as quickly as possible.
In level 1 the ball was fixed to the bar but in subsequent levels the ball was able to move and fall off of the bar [25] . This task tests bimanual coordination.
Object hit (OH)
Participants had to hit as many virtual balls away from them as possible. Balls fell more quickly as the task progressed and the task lasted for a fixed amount of time [23] . This task tests bimanual motor skill. Object hit and avoid (OHA)
Participants had to hit two specific shapes (e.g. a vertical ellipse and a small square) and avoid 6 other distractors [24] . This task tests rapid decision-making processes.
Reverse visually guided reaching (RVGR)
Similar to VGR except the white cursor representing the participant's hand moved in the opposite direction of their hand [27] . This task tests the ability to inhibit an automatic motor response.
Trail making (TMT)
Participants must navigate between targets labeled with numbers (1… 2… etc.; variant A) or numbers and letters (1… 2… etc.; variant B) in order and as quickly as possible. The number of targets was the same in both variants (25) [29, 30] . This task tests processing speed (A) and set-switching (B).
Spatial span (SPS)
A random sequence of square targets was displayed on a 3 × 4 grid which participants were to recall in the same order as shown to them. Sequence length was increased 1 after a successful trial and reduced by 1 after an unsuccessful trial [19, 28] . This task tests spatial working memory capacity. 4.16, p b .001)). There were no statistically significant differences between participants with focal and generalized epilepsy, and none were close to approaching statistical significance.
We additionally compared Task Scores in individuals with left (n = 8) and right TLE (n = 5), see Fig. S1 . We did not identify any differences that reached significance between these two subtypes with these small sample sizes; however, there was a trend (t(13) = 2.31; p = .066) for individuals with right TLE toward performing more poorly on SPS than individuals with left TLE.
Effects of antiepileptic drugs (AEDs)
We investigated differences in performance of individuals in the cohort with epilepsy split on the types of AEDs they were taking, focusing on topiramate and lamotrigine as these are expected to have differential effects on behavior [33] , and they were the most prevalent medications in our cohort (see Fig. S2 ). We identified that, when comparing individuals on topiramate vs not on topiramate, patients on topiramate performed worse on SPS than those not taking this medication (t(46) = 2.92; p = .013); however, this was not statistically significant after Bonferroni correction for FWER. Importantly, by contrast, there were no trends toward significance in the on-vs off-lamotrigine groups (all p N .05).
Relationships between robotic tasks and the MoCA
We tested the correlations between participants' total scores on the MoCA and their Task Score performance on individual robotic tasks using Spearman correlations (see Table 3 ). Three tasks had correlation p-values less than 0.05: APM in the nondominant arm, OHA, and TMT. However, after correcting for the FWER, which reduces the α value from 0.05 to 0.05/11 = 0.0045, only TMT remained significant. 
Discussion
In this work, we demonstrate the feasibility of robotic assessment of a cohort of individuals with epilepsy and identify impairments on motor, cognitive, and sensory tasks. We also explored the effects of antiepileptic drugs (AEDs) and differences between epilepsy subtypes in two separate comparisons: focal vs generalized epilepsy and left vs right TLE.
Our primary finding with this study was that it was feasible to assess individuals with epilepsy using the Kinarm. All participants were able to complete the robotic tasks, with the exception of one participant not having enough time to complete an assessment because they had to leave via prearranged transportation. Additionally, one individual possibly experienced a reflex seizure [34] brought on by trying to recall a medication dosage. Importantly, no participant had an event as a result of the robotic assessment. Future studies should nevertheless continue to exclude participants that are photosensitive to minimize the risk of adverse events, and inquire about history of reflex seizures to prevent any other stimuli from triggering a seizure.
We identified that a large proportion of individuals with epilepsy were impaired on the Kinarm motor tasks. Although the presence of motor/psychomotor deficits in patients with medically refractory seizures who are on AED polytherapy is frequently recognized among neuropsychologists, this area has been understudied in the research literature and remains poorly understood [7, [35] [36] [37] [38] . Importantly, the Kinarm provides a granular assessment of variables describing spatial and temporal features of motor performance, which may prove particularly useful in identifying and characterizing the nature of psychomotor deficits in patients with epilepsy and other neurologic conditions. Some Kinarm tasks also require bimanual planning and control (BOB, OH, and OHA), which provides opportunities to quantify and study bimanual coordination and performance. In the present study, some participants were only impaired in bimanual tasks and not unimanual tasks (see Fig. 2 ). It is possible that some individuals with epilepsy could be more susceptible to deficits in these bimanual tasks, such as those with frontal lobe epilepsy (FLE) [39] .
Cognitive deficits are common in various populations with epilepsy such as temporal lobe epilepsy, frontal lobe epilepsy, and some generalized epilepsies (e.g., juvenile myoclonic epilepsy). Affected domains can include memory, language (e.g., naming and verbal fluency), and executive functions (e.g., card-sorting, response inhibition) [39] [40] [41] [42] [43] . Here, we were able to detect impairments in the ability to perform cognitive Kinarm tasks in the cohort with epilepsy compared to the control cohort [41] . Kinarm tasks such as SPS and TMT test spatial working memory and executive function (specifically set-switching in TMT part B); hence, it was expected that a subset of participants would do poorly on these tasks. Motor response inhibition, a component of executive function [44] , is tested by RVGR. The Kinarm version of TMT correlated significantly with total score on the MoCA, a brief but validated cognitive screening tool. The high frequency of impairment on TMT in this cohort likely reflects that the multiple epilepsy subtypes represented in this study (e.g., generalized epilepsy, TLE, and FLE) can all affect executive function [39, 45] . We also observed a trend toward poorer performance in SPS in individuals with right TLE compared to left TLE, as might be expected [46] [47] [48] , although a larger sample would be required to explore this in-depth. Future work will be required to validate the relationships between specific Kinarm tasks and established neuropsychology testing.
In exploratory analyses, we did not identify any statistically significant differences on Kinarm Task Scores when comparing the subgroup with generalized and subgroup with focal epilepsy. There was a trend toward poorer performance on the Kinarm SPS task in right TLE compared to left TLE, but no differences on the other tasks. However, this feasibility study was underpowered to adequately identify subgroup differences in this cohort, given the small sample sizes. It would be appropriate for future studies to consider these subgroups separately or focus upon one or two specific etiologies, given distinct characteristics and performance anticipated in each of the subgroups [39, 45, [49] [50] [51] . Similarly, in the future, study of individual Kinarm task parameters may assist in further clarifying the nature of motor and cognitive deficits in epilepsy detected by these paradigms, rather than considering only the aggregate Task Scores. Future studies should also determine whether impairments on Kinarm tasks, particularly those testing cognitive domains such as executive function, have a similar association with magnetic resonance imaging (MRI) findings as with traditional cognitive tests [52] .
Interestingly, we were able to detect a moderate deleterious effect of topiramate on SPS, which was not observed with lamotrigine (although it should be noted that the statistical significance of the topiramate effect did not survive correction for multiple comparisons). We focused on these two medications because they were the two most prevalent AEDs in this study. Topiramate, but not lamotrigine, is known to affect working memory and language processing [8, 33, 53, 54] . Although we observed an effect of topiramate on SPS, we did not observe motor slowing as has been demonstrated to occur with topiramate administration [8, 55] . It is possible that motor deficits induced by this drug are subtle, and as a result of the relatively low number of participants taking this medication, our study was simply not powered to observe them. Prior work has identified potential effects of AEDs on balance, which relates to both sensory feedback processing and lower limb motor function, and that lamotrigine may have a milder impact on balance than other AEDs [56, 57] .
Our study has some limitations. One of the clearest is the combination of our relatively small sample size and its heterogeneity, which made it impossible to generalize about impairments related to specific groups of participants. Future studies will ideally focus on one or two epilepsy subtypes.
Our consideration of the feasibility of robotic assessment highlights both the ability of this approach to quantify certain aspects of sensorimotor and cognitive performance in detail, and also provides insight into the limitations of our approach. Kinarm robotic assessment can provide considerable depth of information on traditional kinematic measures that can be used to test goal-directed movements very effectively in a variety of contexts. However, some sensorimotor tasks are not considered here such as the ability to make rapid alternating movements, or fine motor skills such as the ability to track moving targets. Additionally, although we collect data on cognitive tasks in the present study, and indeed over 40% of those in the cohort with epilepsy were impaired on the trail making test, we presently either 1) do not or 2) are not able to test some other aspects of cognition, such as, language or episodic memory, which can be impaired in individuals with epilepsy [4] . A limitation that we may be able to address moving forward is in the area of nonspatial memory, such as semantic memory that might be tested by assessing the ability to recall a concept of a presented object. Other cognitive aspects may be harder to assess using a paradigm like ours at any point in the future. For example, any test requiring verbal p-Values less than 0.05 are bolded, and p-values that were significant after FWER correction (p = .0045, i.e., 0.05/11 comparisons) are bolded with an asterisk (*).
processing (e.g., the California Verbal Learning Test) or mood status (e.g., the Beck Depression Inventory) would be very difficult to replicate using robotic assessment.
There are a few additional limitations to consider for our study in general. Although we demonstrated that we could possibly identify drug-related trends (topiramate), it would be impossible to account for interactions between different medications. We note that, although a trend toward an effect on SPS performance was observed in individuals taking topiramate, our study was not powered to comment further on this. Future studies should keep medication types as consistent as possible to adequately comment on group effects. Finally, Task Scores are aggregates of many variables and thus could cause information loss. Future studies will be able to investigate specific parameters in greater detail now that we have demonstrated that this technology is feasible to use with this population. Future work should additionally consider validating cognitive robotic assessments against conventional neuropsychological assessment.
Conclusions
We performed a broad, quantitative robotic assessment of individuals with epilepsy to determine the feasibility of using this technology with this population, and to describe impairments across several epilepsy subtypes with the objective of informing future, more detailed studies. We report that this approach is feasible with individuals with epilepsy, with no adverse events reported. Finally, we identified that a considerable number of individuals with epilepsy had abnormal performances on motor tasks, and that our assessment was able to detect expected impairments on cognitive tasks.
Supplementary data to this article can be found online at https://doi. org/10.1016/j.yebeh.2019.106859.
